Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography.

Fecha de publicación:

Autores de CIPF

Participantes ajenos a CIPF

  • Torregrosa I
  • Andrés-Costa MJ
  • Giménez-Garzó C
  • Juan I
  • Puchades MJ
  • Blasco ML
  • Carratalá A
  • Sanjuán R
  • Miguel A

Grupos de Investigación

Abstract

Acute kidney injury (AKI) is a common complication after coronary angiography. Early biomarkers of this disease are needed since increase in serum creatinine levels is a late marker. To assess the usefulness of urinary kidney injury molecule-1 (uKIM-1), neutrophil gelatinase-associated lipocalin (uNGAL) and liver-type fatty acid-binding protein (uL-FABP) for early detection of AKI in these patients, comparing their performance with another group of cardiac surgery patients. Biomarkers were measured in 193 patients, 12 h after intervention. In the ROC analysis, AUC for KIM-1, NGAL and L-FABP was 0.713, 0.958 and 0.642, respectively, in the coronary angiography group, and 0.716, 0.916 and 0.743 in the cardiac surgery group. Urinary KIM-1 12 h after intervention is predictive of AKI in adult patients undergoing coronary angiography, but NGAL shows higher sensitivity and specificity. L-FABP provides inferior discrimination for AKI than KIM-1 or NGAL in contrast to its performance after cardiac surgery. This is the first study showing the predictive capacity of KIM-1 for AKI after coronary angiography. Further studies are still needed to answer relevant questions about the clinical utility of biomarkers for AKI in different clinical settings.

Datos de la publicación

ISSN/ISSNe:
0910-8327, 1615-2573

HEART AND VESSELS  SPRINGER

Tipo:
Article
Páginas:
703-711
PubMed:
24989970

Citas Recibidas en Web of Science: 59

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute kidney injury, Biomarkers, Cardiac surgery, Coronary angiography, KIM-1, L-FABP, NGAL

Proyectos asociados

Identificación de un panel de metabolitos en sangre útil par

Investigador Principal: VICENTE FELIPO ORTS

CONSELLERIA DE SANIDAD . 2015

Compartir